Featured Research Search Results

Studying a New PARP Inhibitor and Hormonal Therapy to Treat HER2-negative, HR-positive Metastatic Breast Cancer with a BRCA1, BRCA2, or PALB2 Mutation (EvoPAR BR01)

Clinicaltrials.gov identifier:
NCT06380751

Treatment
Phase 3 treatment study for HER2-negative, HR-positive metastatic breast cancer with a BRCA1, BRCA2 or PALB2 mutation

An Online Program to Help Asian American Breast Cancer Survivors Manage Pain and Depression

Clinicaltrials.gov identifier:
NCT06085313

Quality of Life
Quality of life study for Asian American breast cancer survivors

Treating Advanced or Metastatic Cancers with a New PARP Inhibitor (GS-0201) Alone or Combined with Other Drugs

Clinicaltrials.gov identifier:
NCT06167317

Treatment
Treatment study for people with advanced or metastatic solid tumors

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

Clinicaltrials.gov identifier:
NCT04251052

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

Understanding the Needs of LGBTQIA+ Caregivers Supporting People with Cancer

Surveys, Registries, Interviews
Survey and interview for LGBTQIA+ caregivers supporting people with cancer

HEAL-ABC Study: Harnessing E-Mindfulness Approaches for Living-After Breast Cancer

Clinicaltrials.gov identifier:
NCT06748222

Quality of Life
Quality of life study for young breast cancer survivors who have symptoms associated with depression

Clinical and Molecular Studies of Li-Fraumeni Syndrome and TP53-Associated Disorders

Clinicaltrials.gov identifier:
NCT04367246

Surveys, Registries, Interviews
Study for Li-Fraumeni Syndrome patients, family and household members

Using the Drug eRapa to Prevent the Growth of Polyps in People with Familial Adenomatous Polyposis (SERENTA)

Clinicaltrials.gov identifier:
NCT06950385

Prevention
Prevention study for people with Familial Adenomatous Polyposis (FAP) who have polyps in the colon or rectum

Treating HER2-negative, Metastatic Breast Cancer with a BRCA or PALB2 Mutation Using a New Drug Combined with Olaparib

Clinicaltrials.gov identifier:
NCT06488378

Treatment
Treatment study for HER2-negative, metastatic breast cancer with a BRCA1/2 or PALB2 mutation

Looking at Tumor DNA Before Chemotherapy to Predict Cancer Recurrence in People with High-Risk, Early-Stage Breast Cancer

Clinicaltrials.gov identifier:
NCT06401421

Treatment
Biomarker study for people with early-stage breast cancer

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

Clinicaltrials.gov identifier:
NCT04995198

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer

Testing a Shorter Course of Chemo- and Immunotherapy for People With Early-Stage Triple-Negative Breast Cancer

Clinicaltrials.gov identifier:
NCT05929768

Treatment
Treatment study for early-stage triple-negative breast cancer

Pancreatic Cancer Screening Study (CAPS5)

Clinicaltrials.gov identifier:
NCT02000089

Prevention
Screening study for people at high risk for pancreatic cancer

Registry for People at Increased Risk for Pancreatic Cancer

Clinicaltrials.gov identifier:
NCT06151223

Surveys, Registries, Interviews
Study collecting blood samples and imaging records of people at high risk of developing pancreatic cancer

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

Clinicaltrials.gov identifier:
NCT05281471

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP)

Clinicaltrials.gov identifier:
NCT05552755

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery

The American Cancer Society’s “VOICES of Black Women” Observational Study

Surveys, Registries, Interviews
Survey for Black women who have never been diagnosed with cancer

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

Clinicaltrials.gov identifier:
NCT04090567

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor